This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Nov 1;78(11):1311-1313.

doi: 10.1001/jamaneurol.2021.2942.

Methylphenidate for Apathy in Alzheimer Disease-Why Should We Care?

Carolyn Fredericks¹

Affiliations

PMID: 34570178
DOI: 10.1001/jamaneurol.2021.2942

Comment

Methylphenidate for Apathy in Alzheimer Disease-Why Should We Care?

Carolyn Fredericks. JAMA Neurol. 2021.

. 2021 Nov 1;78(11):1311-1313.

doi: 10.1001/jamaneurol.2021.2942.

Author

Carolyn Fredericks¹

Affiliation

¹ Department of Neurology, Yale University, New Haven, Connecticut.

PMID: 34570178
DOI: 10.1001/jamaneurol.2021.2942

No abstract available

PubMed Disclaimer

Comment on

Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Mintzer J, Lanctôt KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D; ADMET 2 Research Group. Mintzer J, et al. JAMA Neurol. 2021 Nov 1;78(11):1324-1332. doi: 10.1001/jamaneurol.2021.3356. JAMA Neurol. 2021. PMID: 34570180 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information